

## Synthesis and Crystal Structure of *N-p*-Tolyl-2-acetylamino-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxamide

VASU,<sup>\*1</sup> Madegowda MAHENDRA,<sup>\*2</sup> Beeranahally H. DORESWAMY,<sup>\*\*2</sup> K. A. NIRMALA,<sup>\*1</sup> J. SARAVANAN,<sup>\*3</sup> S. MOHAN,<sup>\*4</sup> Mandayam A. SRIDHAR,<sup>\*2</sup> and Javaregowda S. PRASAD<sup>\*2†</sup>

<sup>\*1</sup> Department of Studies in Physics, Bangalore University, Bangalore-560056, India

<sup>\*2</sup> Department of Studies in Physics, University of Mysore, Manasagangotri, Mysore 570 006, India

<sup>\*3</sup> M. S. Ramaiah College of Pharmacy, Bangalore-560054, India

<sup>\*4</sup> P. E. S College of Pharmacy, Hanumanthanagar Bangalore-560050, India

*N-p*-tolyl-2-acetylamino-4,5,6,7-tetrahydrobenzo[*b*]thiophene-3-carboxamide (**2**) has been synthesized and characterized by X-ray diffraction method. The compound **2** crystallizes in monoclinic space group  $P2_1/c$  with cell parameters  $a = 12.651(8)\text{\AA}$ ,  $b = 12.429(2)\text{\AA}$ ,  $c = 21.752(3)\text{\AA}$ ,  $\beta = 99.138(6)^\circ$  and  $Z = 8$ . The structure exhibits both intra and intermolecular hydrogen bonds.

(Received September 25, 2003; Accepted January 9, 2004; Published on Web March 18, 2004)

Several thiophenes<sup>1,2</sup> and Schiff bases<sup>3,4</sup> have been found to show interesting biological activities, like antitubercular, bacteriostatic and antifungal activities. The concept of




Fig. 1 Chemical structure.

preparing thiophene containing biologically active compounds has stimulated researchers in the pharmaceutical chemistry; it now appears that at least one thiophene analog has been prepared for every important therapeutic compound containing a benzene nucleus. These observations stimulated us to presume that Schiff bases of thiophene would produce new compounds of better biological activity. Some derivatives of thiophenes have been reported<sup>5</sup> to possess analgesic and anti-inflammatory activities. These observations prompted us to synthesize some new thiophene-containing compounds for analgesic and anti-inflammatory activities. In view of the above, compound **2** was synthesized and characterized by X-ray studies.

Initially *p*-tolylcyanoacetamide was condensed with cyclohexanone in the presence of benzene for 10 h. The yielded product (*N-p*-tolyl-cyano-cyclohexylideneacetamide) was

Table 1 Experimental crystallographic data

Formula	C <sub>18</sub> H <sub>20</sub> O <sub>2</sub> N <sub>2</sub> S
Formula weight	328.42
Crystal system	monoclinic
Space group	$P2_1/c$ , $Z = 8$
$a$	12.651(8)\text{\AA}
$b$	12.429(2)\text{\AA}
$c$	21.752(3)\text{\AA}
$\beta$	99.138(6)°
$V$	3376.9(6)\text{\AA}^3
$D_x$	1.292 Mg/m <sup>3</sup>
$2\theta_{\max}$	44.42° with Mo K $\alpha$
No. of reflections used	3764
$R$	0.0689
$(\Delta/\sigma)_{\max}$	0.033
$(\Delta\rho)_{\max}$	0.737 e\text{\AA}^{-3}
$(\Delta\rho)_{\min}$	-0.516 e\text{\AA}^{-3}
Measurement	DipLabo Kappa
Program system	Denzo
Structure determination	SHELXS-97
Refinement	full matrix: SHELXL-97

† To whom correspondence should be addressed.  
E-mail: jsp@uomphysics.net




Fig. 2 ORTEP drawing of molecule **2** at 50% probability.

Table 2 Atomic coordinates and equivalent thermal parameters ( $\text{\AA}^2$ ).

Atom	x	y	z	$U_{eq}$
C1A	0.8973(4)	0.0179(4)	0.0706(2)	0.0490(12)
C2A	0.9147(4)	0.1227(4)	0.0575(2)	0.0500(12)
C3A	0.8754(4)	0.3199(4)	0.0632(2)	0.0605(14)
C4A	0.8528(3)	0.2046(3)	0.07543(19)	0.0405(11)
C5A	0.7723(4)	0.1754(4)	0.1080(2)	0.0509(12)
C6A	0.7529(3)	0.0708(4)	0.1219(2)	0.0493(12)
C7A	0.8159(3)	-0.0107(3)	0.10379(19)	0.0374(11)
N8A	0.8063(3)	-0.1191(3)	0.11975(17)	0.0430(9)
O9A	0.6271(2)	-0.1283(3)	0.12125(18)	0.0638(10)
C10A	0.7164(3)	-0.1720(4)	0.1291(2)	0.0422(11)
C11A	0.7297(3)	-0.2856(3)	0.14701(19)	0.0376(10)
C12A	0.8177(3)	-0.3359(4)	0.18734(19)	0.0409(11)
C13A	0.9124(4)	-0.2783(4)	0.2243(2)	0.0548(13)
C14A	0.9763(5)	-0.3518(5)	0.2718(3)	0.0829(19)
C15A	0.9836(6)	-0.4616(6)	0.2534(3)	0.098(2)
C16A	0.8781(4)	-0.5180(5)	0.2318(3)	0.0691(16)
C17A	0.8035(4)	-0.4418(4)	0.1927(2)	0.0472(12)
S18A	0.68417(9)	-0.48665(10)	0.14997(6)	0.0507(5)
C19A	0.6512(3)	-0.3581(3)	0.12533(19)	0.0386(11)
N20A	0.5559(3)	-0.3328(3)	0.08670(17)	0.0433(9)
O21A	0.4848(2)	-0.4975(3)	0.07763(16)	0.0532(9)
C22A	0.4776(3)	-0.4023(4)	0.0652(2)	0.0428(11)
C23A	0.3808(4)	-0.3566(4)	0.0251(2)	0.0577(13)
C1B	0.5997(4)	-0.2521(4)	0.4222(2)	0.0581(14)
C2B	0.5861(4)	-0.3551(4)	0.4390(3)	0.0638(15)
C3B	0.6368(5)	-0.5492(4)	0.4489(3)	0.0671(15)
C4B	0.6570(4)	-0.4352(4)	0.4314(2)	0.0484(12)
C5B	0.7445(4)	-0.4059(4)	0.4053(3)	0.0705(16)
C6B	0.7595(4)	-0.3018(4)	0.3872(3)	0.0694(16)
C7B	0.6881(3)	-0.2225(3)	0.39531(18)	0.0376(10)
N8B	0.6956(3)	-0.1143(3)	0.37679(16)	0.0409(9)
O9B	0.8721(2)	-0.1051(2)	0.36982(15)	0.0534(9)
C10B	0.7832(3)	-0.0615(3)	0.36495(18)	0.0376(11)
C11B	0.7692(3)	0.0530(3)	0.34922(18)	0.0378(11)
C12B	0.6792(3)	0.1053(4)	0.31269(19)	0.0424(11)
C13B	0.5825(4)	0.0511(4)	0.2755(2)	0.0527(13)
C14B	0.5183(3)	0.1267(4)	0.2300(2)	0.0771(18)
C15B	0.5102(3)	0.2353(4)	0.2531(2)	0.086(2)
C16B	0.6165(4)	0.2912(5)	0.2741(3)	0.0711(16)
C17B	0.6934(4)	0.2130(4)	0.3104(2)	0.0530(13)
S18B	0.81457(10)	0.25479(10)	0.35123(6)	0.0550(5)
C19B	0.8490(3)	0.1247(3)	0.3710(2)	0.0392(11)
N20B	0.9473(3)	0.0958(3)	0.40644(16)	0.0404(9)
O21B	1.0154(3)	0.2606(3)	0.42309(16)	0.0552(9)
C22B	1.0254(3)	0.1641(4)	0.43045(19)	0.0407(11)
C23B	1.1233(4)	0.1144(4)	0.4673(2)	0.0524(13)

$$U_{eq} = (1/3)\sum_i \sum_j U_{ij}(a_i^* a_j^*)(a_i a_j).$$

stirred for one hour at 45 – 50°C in the presence of sulfur, ethanol and diethylamine to obtain 2-amino-3-(*N*-p-tolylcarboxamido-4,5,6,7-tetrahydrobenzo[*b*]thiophene (**1**) (Gewald reaction). A mixture of **1** and acetic anhydride (10 ml) was heated on a steam bath for 2 h and the mixture was cooled and left overnight; the solid was filtered, washed with cold ethanol and recrystallised from ethanol, yielding a colorless crystalline product (**2**). Yield 70%. M. P. 162°C.  $^1\text{H NMR}$  (400 Hz  $\text{CDCl}_3$ ):  $\delta$  1.8 – 2.0(d, 4H,  $-\text{CH}_2$  group).

A single crystal of **2** having dimensions of  $0.2 \times 0.3 \times 0.2$  mm was chosen for X-ray diffraction studies. The measurements were made on a DIPLabo Imaging Plate system with graphite-

Table 3 Hydrogen-bonding geometry ( $\text{\AA}$ ,  $^\circ$ )

D-H...A	H-A	D-A	D-H...A	Symmetry Codes
N8A–H9...O21B	2.13	2.977(3)	146	$2 - x, -1/2 + y, 1/2 - z$
N8B–H10...O21A	2.16	3.003(5)	146	$1 - x, 1/2 + y, 1/2 - z$
C1A–H29...O21B	2.58	3.379(6)	140	$2 - x, -1/2 + y, 1/2 - z$
C1B–H31...O21A	2.52	3.340(6)	143	$1 - x, 1/2 + y, 1/2 - z$
N20B–H4...O9B	2.09	2.746(3)	124	
N20A–H5...O9A	2.12	2.761(3)	123	
C6A–H32...O9A	2.41	2.941(6)	122	
C6B–H43...O9B	2.32	2.884(6)	117	

monochromated radiation (Mo  $K_\alpha$ ). The structure was solved by direct methods and expanded by fourier techniques. All of the non-hydrogen atoms were revealed in the first map, itself. An anisotropic refinement using SHELXL-97 was started at this stage and *R*1 finally converged to 0.0674. The hydrogen atoms were placed at calculated positions and were not refined. Details of the crystal data and refinement are given in Table 1. Table 2 gives the details of the final coordinates and equivalent thermal parameters of non-hydrogen atoms.

There are two molecules in an asymmetric unit. The structure has both intra and intermolecular hydrogen bonds (Table 3). The five-membered and phenyl rings of both molecules are planar with a maximum deviation of 0.018(3) $\text{\AA}$  for C19B. The heterocyclic ring of both molecules are apparently planar with a maximum deviation of 0.268  $\text{\AA}$  for C15A and 0.290  $\text{\AA}$  for C15B. A packing diagram of the molecules shows stacking in pairs when viewed down the *b* axis. These pairs are linked *via* hydrogen bonds which in turn, form a linear chain polymer structure.

## Acknowledgements

The authors would like to express their thanks to DST, Government of India for financial assistance under the project SP/I2/FOO/93.

## References

- (a) E. L. Meghraby, B. Harun, and Mohamed, *J. Pharm. Sci.*, **1982**, *23*, 327. (b) C. E. Taylor, and E. D. Vogel, *J. Org. Chem.*, **1985**, *50*, 1002.
- K. M. Kaninkulov, A. G. Makhsumov, and Amanov, *Khim. F. Zh.*, **1992**, *25*, 73.
- G. P. Ellis and G. B. West, *Prog. Med. Chem.*, **1968**, *5*, 320.
- J. Casaszar and J. Morvay, *Acta Pharm. Hung.*, **1983**, *53*, 121.
- G. Zeni, C. W. Nogueira, R. B. Panatieri, D. O. Silva, P. H. Menezes, A. L. Braga, C. C. Silveira, H. A. Stefani, and J. B. T. Rocha, *Tetra. Lett.*, **2001**, *42*, 7921.